Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal

OBJECTIVE: To examine the impact of withdrawing rosiglitazone and ramipril medication on diabetes incidence after closeout of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. RESEARCH DESIGN AND METHODS: The 3,366 DREAM subjects at trial end who had not dev...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2011
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3114353/
https://www.ncbi.nlm.nih.gov/pubmed/21515846
http://dx.doi.org/10.2337/dc10-1567

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3114353/
https://www.ncbi.nlm.nih.gov/pubmed/21515846
http://dx.doi.org/10.2337/dc10-1567

Ejemplares similares